Tony Gibney Joins InflaRx Board of Directors
May 21 2021 - 7:30AM
InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical
company developing anti-inflammatory therapeutics by targeting the
complement system, today announced Mr. Tony Gibney has been
appointed as a Non-Executive Director to the Board of Directors at
InflaRx. Mr. Gibney is a highly experienced life
sciences-focused biotech executive and former investment banker who
has executed over 150 financings and M&A advisory transactions
for US and European clients. Mr. Gibney's appointment was approved
by InflaRx's shareholders at the 2021 annual shareholder meeting.
Mr. Mark Kübler and Ms. Lina Ma were re-appointed as Non-Executive
Directors to the Board of Directors.
“We are excited that Tony is joining the InflaRx
board. He has tremendous experience in the biotech industry, having
served as a senior executive in the financial sector and in
different companies,” said Prof. Niels C. Riedemann, Chief
Executive Officer and Founder of InflaRx. “Our entire team feels
fortunate about his commitment and willingness to help InflaRx with
its endeavors. We are also very happy to announce the re-election
of Lina Ma and Mark Kübler as board members. Both have contributed
to InflaRx for many years and were instrumental in our successful
IPO in 2017.”
Tony Gibney, Board member of InflaRx, said: "I
am gratified to have been offered the opportunity to return to the
Board of InflaRx, especially at such an important time in the
Company's evolution as the leader in complement C5a inhibition. I
hope that my experience in the complement arena, strategy and
finance can provide incremental support to our strong Board of
Directors and deep leadership team at InflaRx, as we look forward
to multiple value-driving clinical readouts in indications with
critical unmet needs and devastating morbidities. I am
convinced that InflaRx's unique pathway can play an impactful role
for patients."
Tony Gibney is currently the CFO and CBO at
FogPharma, overseeing and driving the business development,
strategy and finance functions of the company. Tony served as the
EVP and CBO of Achillion Pharmaceuticals, Inc. from 2018 to 2020,
where he was responsible for corporate and portfolio strategy,
business development and corporate communications and led the
successful sale of Achillion to Alexion in 2020. Before Achillion,
Tony was a life sciences-focused investment banker for 24 years.
From 2009 through 2018, he served as a managing director and
co-head of the biotechnology investment banking team for Leerink
Partners LLC. From 1999 to 2009, he was a managing director in the
Life Sciences team at Merrill Lynch Inc. and executed a variety of
significant financing and M&A transactions while leading the
firm's East Coast biotechnology effort. Tony began his investment
banking career in the Healthcare Group at Lehman Brothers in 1993.
He graduated from Yale University in 1993 with a B.A. in History
and Economics.
More information on InflaRx's Board is available
at https://www.inflarx.de/Home/About-Inflarx/Board.html.
About InflaRx N.V.:
InflaRx (Nasdaq: IFRX) is a clinical-stage
biopharmaceutical company focused on applying its proprietary
anti-C5a technology to discover and develop first-in-class, potent
and specific inhibitors of C5a. Complement C5a is a powerful
inflammatory mediator involved in the progression of a wide variety
of autoimmune and other inflammatory diseases. InflaRx was founded
in 2007, and the group has offices and subsidiaries in Jena and
Munich, Germany, as well as Ann Arbor, MI, USA. For further
information please visit www.inflarx.com.
Contacts:
InflaRx N.V.Jordan Zwick –
Chief Strategy OfficerEmail: IR@inflarx.deTel: +1 917-338-6523
MC Services AGKatja Arnold,
Laurie Doyle, Andreas Jungfer Email: inflarx@mc-services.eu Europe:
+49 89-210 2280US: +1-339-832-0752
FORWARD-LOOKING STATEMENTSThis
press release contains forward-looking statements. All statements
other than statements of historical fact are forward-looking
statements, which are often indicated by terms such as “may,”
“will,” “should,” “expect,” “plan,” “anticipate,” “could,”
“intend,” “target,” “project,” “believe,” “estimate,” “predict,”
“potential” or “continue” and similar expressions. Forward-looking
statements appear in a number of places throughout this release and
may include statements regarding our intentions, beliefs,
projections, outlook, analyses and current expectations concerning,
among other things, our ongoing and planned preclinical development
and clinical trials; the impact of the COVID-19 pandemic on the
Company; the timing and our ability to commence and conduct
clinical trials; potential results from current or potential future
collaborations; our ability to make regulatory filings, obtain
positive guidance from regulators, and obtain and maintain
regulatory approvals for our product candidates; our intellectual
property position; our ability to develop commercial functions;
expectations regarding clinical trial data; our results of
operations, cash needs, financial condition, liquidity, prospects,
future transactions, growth and strategies; the industry in which
we operate; the trends that may affect the industry or us and the
risks uncertainties and other factors described under the heading
“Risk Factors” in InflaRx’s periodic filings with the Securities
and Exchange Commission. These statements speak only as of the date
of this press release and involve known and unknown risks,
uncertainties and other important factors that may cause our actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements. Given these risks,
uncertainties and other factors, you should not place undue
reliance on these forward-looking statements, and we assume no
obligation to update these forward-looking statements, even if new
information becomes available in the future, except as required by
law.
InflaRx NV (NASDAQ:IFRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
InflaRx NV (NASDAQ:IFRX)
Historical Stock Chart
From Apr 2023 to Apr 2024